A carregar...
A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
LESSONS LEARNED. Patients with metastatic colorectal cancer with good performance status or no liver metastasis could benefit from apatinib. Circulating tumor DNA abundance may be a predictor in serial monitoring of tumor load. BACKGROUND. Apatinib, an oral vascular endothelial growth factor (VEGF)...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6656475/ https://ncbi.nlm.nih.gov/pubmed/30877190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0164 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|